Emscopes Launch Solves Literature Problem For Pharma Companies

Elsevier Unveils A New Complete Way Of Tracking Published Research

Amsterdam, The Netherlands, 7 February, 2007 – Today sees the launch of Emscopes, Elsevier's new flagship product for the pharmaceutical and biomedical industry. Emscopes allows these companies to keep up-to-date with all the latest research on their drugs. Emscopes is the most complete product of its kind to cost-effectively bring together high-quality drug indexing, for which Elsevier is renowned, with the easiest possible online delivery.

Pharmaceutical professionals not involved directly in the scientific process, such as Medical Advisors, Pharmacovigilance, Product Strategy and Sales & Marketing, need a summary of the relevant material. It is important that they be alerted whenever a new side effect is identified in the literature after a drug has been marketed. Emscopes provides pharma personnel with considerable time-savings and substantially reduces the risk of vital information being missed at the clinical trial and post-market surveillance stages.

Emscopes comprehensively scans the world’s scientific literature to identify all drug-related research. The 'Drug-Specific Indexing' technique ensures all detailed drug-related data such as adverse drug reactions, indication and drug comparison, is extracted from the full text and listed in each record to create a comprehensive summary for any drug. The database delivered to the customer is personalized according to pre-defined search criteria so that the information they receive is relevant and up-to-date.

During Emscopes' year in development, users at 20 different companies including Organon and Schering Plough, were given the chance to bring their wants and needs into the final product. Three main priorities were clear from testing the prototypes: it had to be a quick look-up service that did not require search knowledge; it must offer complete coverage of the specific drugs they need to follow; and it should summarize the full-text but provide links to articles as well.

Amanda Spiteri, Director of Bibliographic Databases, says "Never before has the pharmaceutical industry been offered such a complete and hosted service that selectively but comprehensively surveys new research on a drug. Elsevier’s track record of quality data provision and cutting-edge technology meant we were best placed to develop such a tailored offering. In addition to our new and fast ‘Drug-Specific Indexing’ process, Emscopes marks a great advancement in drug information provision."

Boston, Massachusetts, will be the setting for the first public viewing of Emscopes. The Pharmaceutical & Health Technology division of the Special Librarians Association (SLA P&HT) will hold its annual spring meeting at the Sheraton Hotel on March 18-20. Delegates are invited to visit the exhibition and find out more.


About Emscopes
Emscopes is a unique way for Pharma BioMed companies to keep up-to-date with all the published research about their drugs. Emscopes is a service that comprehensively searches the biomedical literature to extract and summarize all detailed drug-related information such as Dosage, Adverse Drug Reactions, Concomitant Use, Drug Combination, Indication and Administration Route. On a customer-by-customer basis a tailored search is performed on the drugs each company needs to follow – their own and often competitors. The result is a bespoke product literature database solution that is available online for everyone in the company. It is specifically designed for pharmaceutical personnel not directly involved in the scientific process. So for Medical Advisors, Regulatory Affairs, Sales & Marketing, Business Intelligence and other strategic groups, it’s like having a competent personal assistant to read and summarize all the relevant articles for them.

Emscopes is offered as an annual subscription on a price-per-drug basis.

Visit www.info.emscopes.com for more information.

About Elsevier
Elsevier is a global information analytics business that helps scientists and clinicians to find new answers, reshape human knowledge, and tackle the most urgent human crises. For 140 years, we have partnered with the research world to curate and verify scientific knowledge. Today, we’re committed to bringing that rigor to a new generation of platforms. Elsevier provides digital solutions and tools in the areas of strategic research management, R&D performance, clinical decision support, and professional education; including ScienceDirect, Scopus, SciVal, ClinicalKey and Sherpath. Elsevier publishes over 2,500 digitized journals, including The Lancet and Cell, 39,000 e-book titles and many iconic reference works, including Gray's Anatomy. Elsevier is part of RELX, a global provider of information-based analytics and decision tools for professional and business customers. www.elsevier.com

Media Contact:
Ann-Marie Roche
+31 20 485 3542